Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
Caribou Biosciences Inc. is a pioneering biotechnology firm specializing in genome editing through its proprietary CRISPR technology, aimed at developing transformative therapies for genetic disorders and oncology. With a robust and diversified pipeline addressing significant unmet medical needs, the company is well-positioned to lead advancements in precision medicine. Caribou's strategic collaborations and unwavering commitment to research excellence underpin its mission to revolutionize treatment paradigms and improve patient outcomes, establishing its foothold as a key player in the biopharmaceutical sector.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$1.54
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Jun 30, 2026 Reported Aug 12, 2026 | $-0.33 | $-0.24 | Beat +27.3% | $-0.24 | $2.2M | $1.5M | -31.8% | 1D Pre+1.8% | On-Day+0.6% | 1D Post-5.3% |
Q ended Mar 31, 2026 Reported May 7, 2026 | $-0.31 | $-0.26 | Beat +16.1% | $-0.26 | $2.2M | $2.4M | +9.1% | 1D Pre+1.0% | On-Day-3.6% | 1D Post+3.2% |
Q ended Dec 31, 2025 Reported Mar 5, 2026 | $-0.32 | $-0.28 | ||||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| — |
| $2.0M |
| $3.9M |
| +95.0% |
| 1D Pre+2.3% |
| On-Day-5.0% |
| 1D Post+6.4% |
Q ended Sep 30, 2025 Reported Nov 12, 2025 | $-0.35 | $-0.30 | Beat +14.3% | — | $1.9M | $2.2M | +15.8% | 1D Pre+8.2% | On-Day+0.9% | 1D Post-12.2% |